title: [Seven or ten days? Cost-effectiveness study on the duration of H. pylori treatment in primary care].
abstract: OBJECTIVE
  To determine through an economic evaluation study whether it is cost-effective to extend treatment of dyspeptic patients from 7 to 10 days, distinguishing between functional dyspepsia, unexamined dyspepsia, and ulcer disease.
  
  
  METHODS
  Cost-effectiveness study by means of a decision 3 comparing direct costs per patient cured with 2 strategies: a) 7 days treatment versus b) 10 days. Two-year study in the National Health System.
  
  
  METHODS
  Primary care.
  
  
  METHODS
  One-hundred patients with peptic ulcer, functional dyspepsia, or unexamined dyspepsia who received treatment for H pylori infection.
  
  
  METHODS
  H pylori eradication treatment with a proton pump inhibitor, clarithromycin, and amoxycillin for 7 or 10 days. Measurement variable: incremental cost per patient cured.
  
  
  RESULTS
  In peptic ulcer patients, the incremental cost per patient cured on extending the eradication treatment from 7 to 10 days was euro147 (95% CI, 121.3-162.7), whereas in patients with functional or unexamined dyspepsia, it was -euro39.8 (95% CI, -28.5 to -60.7) and -euro27.3 (95% CI, -14.92 to -52.72), respectively. The sensitivity analysis showed that the efficacy of eradication treatment (7 vs 10) was the factor that most affected the stability of the results.
  
  
  CONCLUSIONS
  Seven days is the most cost-effective duration of the triple therapy for eradicating H pylori in ulcer patients. However, 10 days is more cost-effective in functional dyspepsia patients or those with no prior endoscope diagnosis.
authors.affiliation: Servei d'Urgències, Hospital de Sabadell, Corporació Parc Taulí, Barcelona, España. 29833egt@comb.es
authors.forename: Emili
authors.initials: E
authors.lastname: Gené
authors.forename: Xavier
authors.initials: X
authors.lastname: Calvet
authors.forename: Rafael
authors.initials: R
authors.lastname: Azagra
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D003362:Cost-Benefit Analysis; D003663:Decision Trees; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics*; D016480:Helicobacter pylori; D006801:Humans; D011320:Primary Health Care; D013997:Time Factors